The Science of Grass Jelly: From Traditional Dessert to Medical Breakthrough?

Grass jelly, widely known as cincau in Indonesia, is a beloved traditional Southeast Asian dessert that originates from three distinct plant species. Despite over a century of laboratory studies investigating its health benefits, there is currently no clinical therapeutic use for the plant. A comprehensive 2026 review published in Terra Alimentaria unpacks the phytochemistry, pharmacological potential, and the missing links needed to turn this cultural staple into a validated clinical therapy.

The Three Faces of Grass Jelly

While they share a culinary purpose, traditional grass jelly is derived from three phylogenetically distinct plants:

• Black Grass Jelly (Platostoma palustre): Belonging to the Lamiaceae family, this herbaceous plant is traditionally prepared by boiling dried leaves and stems with alkaline ash and starch. Recent genomic studies have identified 1,228 metabolites in this plant, heavily featuring phenolic acids and flavonoids.
• Creeping Green Grass Jelly (Cyclea barbata): Part of the Menispermaceae family, this creeping vine naturally gels when its fresh leaves are crushed in water due to the interaction of endogenous pectin methyl esterase and calcium. It is notably rich in bisbenzylisoquinoline alkaloids, particularly tetrandrine, which can make up to 3% of the root weight.
• Shrub Grass Jelly (Premna trichostoma): Also from the Lamiaceae family, this shrub is prepared similarly to creeping green grass jelly through natural gelation. It is exceptionally rich in chlorophyll and serves as a potential source of dietary fiber with antioxidant properties.

Pharmacological Potential vs. The Evidence

Extensive preclinical data highlights the medicinal potential of grass jelly, though researchers urge caution regarding how these results are interpreted:

• Antioxidant Activity: Grass jelly species exhibit extensive antioxidant activity across multiple assays. However, current evidence is limited to in vitro assays using crude extracts, and colored compounds like chlorophyll may artificially interfere with the results.
• Antidiabetic Effects: Preclinical in vivo models show significant promise, with P. palustre extracts combined with glibenclamide reducing fasting blood glucose by 37.1%.
• Cardiovascular Health: Studies indicate that M. palustris treatments can reduce cholesterol levels by 50.01% and increase HDL by 36.47% in mice. Furthermore, P. trichostoma chlorophyll extracts suppressed LDL by 83.65% in hypercholesterolemic rats.
• Anticancer Properties: C. barbata yields specific alkaloids that have demonstrated the ability to inhibit cancer cell growth through multiple mechanisms. Additionally, P. palustre reduced cancer incidence by 57% in one in vivo model, though this specific finding requires further confirmation.

Material Science and Veterinary Applications

Beyond human nutrition, the unique properties of grass jelly are being explored in other scientific fields:

• Sperm Cryopreservation: Supplementing skim milk yolk-based semen extenders with a 2% black cincau leaf extract maintained sperm motility and improved conception rates in Boer goats from 63.33% to 80%.
• Wound Healing and Hydrogels: The unique gel-forming polysaccharides in grass jelly make it an excellent base for biodegradable hydrogels and wound-healing scaffolds. For example, C. barbata pectin blended with chitosan significantly improved wound closure in vivo.

The Seven Systemic Gaps in Grass Jelly Research

If grass jelly is so promising, why isn’t it a registered drug? The review identifies seven systemic deficiencies holding the research back:

1. The Extractology Problem: The vast majority of research relies on crude extracts rather than isolated active compounds, halting the advancement of mechanistic understanding.
2. The Attribution Problem: Many trials evaluate multi-herb mixtures, making it impossible to attribute observed benefits strictly to the grass jelly.
3. Compound Identification Gaps: No definitive active compounds have been proven responsible for the plant’s various pharmacological effects.
4. Mechanistic Uncertainty: Without identifying exact active compounds, researchers cannot determine precise molecular mechanisms.
5. Pharmacokinetic Absence: There is currently zero data on the bioavailability, metabolism, or tissue distribution of grass jelly compounds.
6. Integration Fragmentation: Research exists in isolated disciplinary silos without cross-collaboration.
7. Translational Failure: There are currently no direct clinical trials testing any grass jelly species as a therapeutic agent.

A Five-Phase Roadmap for the Future

To transition grass jelly from a descriptive botanical curiosity into a mechanistic pharmacological asset, researchers propose a structured five-phase framework. This roadmap spans from initial compound identification and mechanistic elucidation to pharmacokinetic profiling and eventual clinical validation. If funded and executed properly, this approach could elevate grass jelly from a refreshing regional dessert to a global model for sustainable phytochemical discovery.

See more about this from here: Frediansyah, A., Kurniawan, D., Ramadaningrum, W. A., Aziz, S. A. A., Utomo, A. R. P., Pramono, A. K., & Siregar, A. R. (2026). Grass Jelly Species (Platostoma palustre, Premna trichostoma, and Cyclea barbata): Phytochemistry, Pharmacology, and Translational Potential—A Review. Terra Alimentaria, 1(1), e2026001. https://journals.nusaxis.com/terra/article/view/2